# Cyagen US

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cyagen-us

- Industry: Biotechnology
- Headquarters: Santa Clara, US
- Website: www.cyagen.com
- Total disclosed funding: $41M
- Latest round: Series B (Feb 26, 2020)
- Investors on record: 5

## About

Cyagen US Inc. is a biosciences company specializing in advanced preclinical research solutions, particularly in genetic engineering and model development for therapeutic research.Founded in 2005, Cyagen US Inc. is headquartered in Santa Clara, US. The company focuses on providing preclinical research solutions and has undergone significant growth since its establishment. In February 2020, Cyagen raised RMB 285 million in Series B funding, primarily targeting advancements in its genetic engineering technologies. The funding round attracted multiple new investors, enhancing Cyagen's financial position for future projects.Cyagen Biosciences specializes in advanced preclinical research solutions, offering a comprehensive suite of products and services focused on genetic engineering and model development. Their core offerings include genetically engineered animals, custom cell lines, and virus packaging solutions tailored for research in therapeutic areas such as oncology, ophthalmology, and neuroscience. Cyagen provides essential models that replicate human diseases, enabling efficient drug discovery and development. Their flagship products include the HUGO-GT™ humanization models and various knockout and knockin models designed to meet the precise needs of biomedical researchers. Cyagen serves a global client base across North America, Europe, and the Asia-Pacific regions, including academic institutions, pharmaceutical companies, and biotechnology firms engaged in scientific research.Cyagen Biosciences generates revenue through a structured transaction model encompassing both custom services and product sales. Clients typically engage with the company for preclinical research projects, resulting in contracts that may include the development of custom genetically engineered animals or cell lines, as well as virus packaging services. The company offers tiered pricing structures tailored to specific projects, including a 50% discount on initial iPSC editing projects for new clients. Partnerships and collaborations with global bioscience organizations further enhance Cyagen's revenue streams, facilitating access to a wider customer base. The combination of direct sales and collaborative partnerships positions Cyagen as a key player in the preclinical research landscape, ensuring a steady flow of business through ongoing client engagements and project-based transactions.Cyagen's strategy for future growth hinges on the development of new products and expansion into new markets. The company plans to launch innovative genetically engineered models tailored for specific therapeutic areas by the end of 2022. Additionally, Cyagen aims to expand its presence in European and Asian markets, targeting significant growth in these regions by 2025. The recent Series B funding of RMB 285 million will be utilized to support these initiatives, enhancing product development capabilities and expanding the company's operational footprint in strategic global markets.

## Funding rounds

- Series B, Feb 26, 2020, $41M — GF Xinde Investment, China Merchants Securities Zhiyuan Capital, GF Qianhe, Grower Venture Capital
- Series A, Aug 12, 2016 — LYFE Capital

## Investors

- LYFE Capital — Series A
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series B
- China Merchants Securities Zhiyuan Capital (https://capitalatlas.ai/funds/china-merchants-securities-zhiyuan-capital) — Series B
- GF Qianhe — Series B
- Grower Venture Capital (https://capitalatlas.ai/funds/grower-venture-capital) — Series B